Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patients


Sannino G., Marchetto A., Ranft A., Jabar S., Zacherl C., Alba-Rubio R., ...Daha Fazla

EBIOMEDICINE, cilt.47, ss.156-162, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 47
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.ebiom.2019.08.002
  • Dergi Adı: EBIOMEDICINE
  • Sayfa Sayıları: ss.156-162

Özet

Background: Up to 30-40% of Ewing sarcoma (EwS) patients with non-metastatic disease developlocal or metastatic relapse within a time span of 2-10 years. This is in part caused by the absence of prognostic biomarkers that can identify high-risk patients and thus assign them to risk-adapted monitoring and treatment regimens. Since cancer stemness has been associated with tumour relapse and poor patient outcomes, we investigated in the current study the prognostic potential of SOX2 (sex determining region Y box 2) - a major transcription factor involved in development and stemness - which was previously described to contribute to the undifferentiated phenotype of EwS.